News about Vaccinex Inc

Vaccinex Expands Horizons with Innovate ActivMAb Platform Pioneering Antibody Discovery in Cancer Immunotherapy
Nov 07 2024
In a robust display of innovation, Vaccinex Inc. has recently provided exciting updates on its proprietary ActivMAb platform, a revolutionary technolo...

Promising Biomarker and Cognitive Treatment Effects from Vaccinexs Pepinemab in Alzheimer?s Disease
Oct 31 2024
Overview of Pepinemab and its Phase 1b/2 TrialVaccinex Inc. recently presented new findings from the SIGNAL-AD Phase 1b/2 clinical trial of its inves...

Vaccinex Inc. Secures $6.2 Million from Warrant Exercises in Strategic Move to Bolster Operations Amid Q3 Challenges,
Sep 18 2024
Vaccinex Inc. Secures $6.2 Million from Warrant Exercises in Strategic Move to Bolster Operations Amid Q3 ChallengesRochester, N.Y., Sept. 18, 2024 ...

Vaccinex Inc. Showcases Strategic Advancements in Alzheimers Disease Research and Financial Performance
Aug 14 2024
Vaccinex Inc., a biotechnology company dedicated to developing therapeutics for neurological diseases, has made significant strides in its clinical an...

Evolving Alzheimers Treatment Promising Phase 1b/2 Trial Results for Vaccinexs Pepinemab Highlight Nov...
Jul 31 2024
Understanding the Promise of Pepinemab: A Novel Approach for Alzheimer s Disease The quest for viable treatments for Alzheimer s disease (AD) remains ...

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimers Disease at the Alzheimers A...
Jul 17 2024
Unveiling Hope: Vaccinex to Present Promising Topline Data for Pepinemab in Alzheimer s Disease at AAIC 2024The relentless quest for a breakthrough i...

Vaccinex Completes Crucial Milestone in Alzheimers Trial: Data Revealing Potential Breakthrough Treatment...
Jun 06 2024
Patient visits conclude in Alzheimer?s disease clinical trial; Data expected to be presented in July following database lock in June. Vaccinex, Inc. r...

Vaccinex*s Financial Moves Pave the Way for Innovative Alzheimer*s and Cancer Therapies
Mar 27 2024
Vaccinex Announces Agreements for Stock Offering and Reverse Stock SplitRochester, N.Y. - In a recent press release, Vaccinex, Inc. (Nasdaq: VCNX...

Vaccinex Expands Access to ActivMAb Antigen Virus Technology Through Eight New Agreements
Feb 21 2024
In a breakthrough announcement, Vaccinex Inc., a renowned clinical-stage biotechnology company, has unveiled multiple strategic agreements that grant ...

Vaccinex, Inc. Reverse Stock Split: A Boost or a Bust for Investors
Feb 15 2024
Vaccinex, Inc. Announces Reverse Stock Split: What This Means for InvestorsIn a press release issued on February 15, 2024, Vaccinex, Inc. (NASDAQ...

Major Pharmaceutical Company Faces Uphill Battle in Q3 2023: A Closer Look at Vaccinex Inc*s Struggles
Nov 14 2023
Vaccinex Inc, a major pharmaceutical preparations company, recently announced the successful completion of Phase 1/2a randomized SIGNAL-AD study of Pe...